A systematic review with meta-analysis of RCTs in patients with type 2 diabetes demonstrated that GLP-1 RAs significantly reduce composite MACE (CV death, nonfatal myocardial infarction, and nonfatal stroke) by 14% and all-cause mortality by 12%. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.